Clinical Trial Update: Phase 2 Study of Alisertib (MLN8237) in Combination With Paclitaxel Versus Placebo in Combination With Paclitaxel as Second Line Therapy for Small Cell Lung Cancer (SCLC) [Phase 2]

View source ↗

Summary

Phase 2 study evaluating alisertib plus paclitaxel vs placebo plus paclitaxel as second-line therapy for small cell lung cancer has completed with results poste…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Small Cell Lung Cancer

Drugs mentioned

• Alisertib (alisertib)
• PACLITAXEL (PACLITAXEL)

Snippet

Sponsor: Millennium Pharmaceuticals, Inc. | Conditions: Small Cell Lung Cancer | Phase 2 | Status: COMPLETED | Results posted: 2018-12-27